These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 35191283)

  • 21. Crbn-based molecular Glues: Breakthroughs and perspectives.
    An J; Zhang X
    Bioorg Med Chem; 2024 Apr; 104():117683. PubMed ID: 38552596
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation.
    Maniaci C; Hughes SJ; Testa A; Chen W; Lamont DJ; Rocha S; Alessi DR; Romeo R; Ciulli A
    Nat Commun; 2017 Oct; 8(1):830. PubMed ID: 29018234
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design Principles Involving Protein Disorder Facilitate Specific Substrate Selection and Degradation by the Ubiquitin-Proteasome System.
    Guharoy M; Bhowmick P; Tompa P
    J Biol Chem; 2016 Mar; 291(13):6723-31. PubMed ID: 26851277
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structure driven compound optimization in targeted protein degradation.
    Leissing TM; Luh LM; Cromm PM
    Drug Discov Today Technol; 2020 Dec; 37():73-82. PubMed ID: 34895657
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and Evaluation of Cereblon-Recruiting HaloPROTACs.
    Ody BK; Zhang J; Nelson SE; Xie Y; Liu R; Dodd CJ; Jacobs SE; Whitzel SL; Williams LA; Gozem S; Turlington M; Yin J
    Chembiochem; 2023 Nov; 24(21):e202300498. PubMed ID: 37625128
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exploiting ELIOT for Scaffold-Repurposing Opportunities: TRIM33 a Possible Novel E3 Ligase to Expand the Toolbox for PROTAC Design.
    Palomba T; Tassone G; Vacca C; Bartalucci M; Valeri A; Pozzi C; Cross S; Siragusa L; Desantis J
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430693
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Perspectives on the development of first-in-class protein degraders.
    Rambacher KM; Calabrese MF; Yamaguchi M
    Future Med Chem; 2021 Jul; 13(14):1203-1226. PubMed ID: 34015962
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted Protein Degradation through E2 Recruitment.
    Forte N; Dovala D; Hesse MJ; McKenna JM; Tallarico JA; Schirle M; Nomura DK
    ACS Chem Biol; 2023 Apr; 18(4):897-904. PubMed ID: 36940189
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemically Induced Cellular Proteolysis: An Emerging Therapeutic Strategy for Undruggable Targets.
    Moon S; Lee BH
    Mol Cells; 2018 Nov; 41(11):933-942. PubMed ID: 30486612
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Modular Chemistry Platform for the Development of a Cereblon E3 Ligase-Based Partial PROTAC Library.
    Almodóvar-Rivera CM; Zhang Z; Li J; Xie H; Zhao Y; Guo L; Mannhardt MG; Tang W
    Chembiochem; 2023 Oct; 24(20):e202300482. PubMed ID: 37418320
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of E3 Ligase Ligands for Target Protein Degradation.
    Lee J; Lee Y; Jung YM; Park JH; Yoo HS; Park J
    Molecules; 2022 Oct; 27(19):. PubMed ID: 36235052
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proteasome substrate receptors and their therapeutic potential.
    Osei-Amponsa V; Walters KJ
    Trends Biochem Sci; 2022 Nov; 47(11):950-964. PubMed ID: 35817651
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expanding PROTACtable genome universe of E3 ligases.
    Liu Y; Yang J; Wang T; Luo M; Chen Y; Chen C; Ronai Z; Zhou Y; Ruppin E; Han L
    Nat Commun; 2023 Oct; 14(1):6509. PubMed ID: 37845222
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Small-Molecule Degraders beyond PROTACs-Challenges and Opportunities.
    Kastl JM; Davies G; Godsman E; Holdgate GA
    SLAS Discov; 2021 Apr; 26(4):524-533. PubMed ID: 33632029
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A label-free quantitative proteomics strategy to identify E3 ubiquitin ligase substrates targeted to proteasome degradation.
    Burande CF; Heuzé ML; Lamsoul I; Monsarrat B; Uttenweiler-Joseph S; Lutz PG
    Mol Cell Proteomics; 2009 Jul; 8(7):1719-27. PubMed ID: 19376791
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systematic approaches to identify E3 ligase substrates.
    Iconomou M; Saunders DN
    Biochem J; 2016 Nov; 473(22):4083-4101. PubMed ID: 27834739
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation.
    Xi M; Chen Y; Yang H; Xu H; Du K; Wu C; Xu Y; Deng L; Luo X; Yu L; Wu Y; Gao X; Cai T; Chen B; Shen R; Sun H
    Eur J Med Chem; 2019 Jul; 174():159-180. PubMed ID: 31035238
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemical approaches to targeted protein degradation through modulation of the ubiquitin-proteasome pathway.
    Collins I; Wang H; Caldwell JJ; Chopra R
    Biochem J; 2017 Mar; 474(7):1127-1147. PubMed ID: 28298557
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Advances in the preclinical and clinical research of proteolysis targeting chimera].
    Liu Z; Liu S
    Sheng Wu Gong Cheng Xue Bao; 2023 Sep; 39(9):3615-3627. PubMed ID: 37805842
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HECT ubiquitin ligases as accessory proteins of the plant proteasome.
    Wang Z; Spoel SH
    Essays Biochem; 2022 Aug; 66(2):135-145. PubMed ID: 35635104
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.